Anthony F. Shields
Abstract
Further development and validation of 18F-labeled 3′-deoxy-3′fluorothymidine (FLT) is presented by Buck et al. in this issue of The Journal of Nuclear Medicine ([1][1]). Although the use of PET has exploded within the last few years, this has primarily resulted from the application of 18F-FDG in
OpenAlex reports 117 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Further development and validation of 18F-labeled 3′-deoxy-3′fluorothymidine (FLT) is presented by Buck et al. in this issue of The Journal of Nuclear Medicine ([1][1]). Although the use of PET has exploded within the last few years, this has primarily resulted from the application of 18F-FDG in
Key concepts: Nuclear medicine, Nuclear imaging, Pet imaging, Thymidine, Medicine, Chemistry, Positron emission tomography, Cancer research